Meningitis B Vaccination Clinic (Bexsero)
Comprehensive protection against invasive Meningococcal B bacteria for infants, teenagers, university students, and high-risk travellers.
Clinical Overview & Importance
Meningococcal group B (MenB) is the most common cause of bacterial meningitis and septicaemia (blood poisoning) in the United Kingdom. MenB disease is life-threatening and progresses rapidly within 24 hours, presenting with high fever, stiff neck, sensitivity to light, confusion, and a non-blanching purpuric rash. Vaccination with Bexsero stimulates the immune system to produce antibodies against MenB surface proteins, providing proven clinical protection.
Why Vaccination Matters
While the NHS routine childhood immunisation programme covers MenB for infants born after May 2015, older children, teenagers, and young adults entering university or communal living are at elevated risk of contracting MenB and are not routinely covered by NHS programmes. Our private clinical service bridges this vital protection gap under accredited Patient Group Directions (PGD).
Who Should Receive This Vaccination?
- Infants and toddlers from 8 weeks of age not covered by routine NHS scheduling
- Adolescents and young adults (ages 14 to 25), particularly new university students in shared halls of residence
- Adults with asplenia, splenic dysfunction, or complement deficiency disorders
- Travellers visiting high-prevalence areas or sub-Saharan meningitis belt regions
- Occupational healthcare and laboratory workers exposed to meningococcal isolates
Recommended Dosing & Schedule
| Age / Cohort | Primary Schedule | Booster Dose |
|---|---|---|
| Infants (2 to 5 months) | 2 doses (separated by at least 2 months) | 1 booster dose at 12 to 15 months |
| Infants (6 to 11 months) | 2 doses (separated by at least 2 months) | 1 booster dose in the second year of life |
| Children (12 to 23 months) | 2 doses (separated by at least 2 months) | 1 booster dose 12–23 months after primary series |
| Adolescents & Adults (2+ years) | 2 doses (separated by at least 1 month) | No booster currently recommended for healthy individuals |
Frequently Asked Questions
- One-on-one pre-vaccination clinical assessment with our trained duty pharmacist.
- Verification of medical history, allergies, and concurrent medications.
- Intramuscular injection administered in the upper arm (deltoid) or anterolateral thigh.
- Paracetamol guidance provided for infants to mitigate post-vaccine fever.
- Post-immunisation observation period in our clinic lounge.